XPG is a novel biomarker of clinical outcome in advanced non-small-cell lung cancer

Ye, Yi; Sun, Zhe; Wang, Xia; Si-qing, LI; Wu, Zhenxuan; Zhu, Yichao; Sun, Bing; Cui, Junwei

doi:10.12669/pjms.293.3664

Cited by 11 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our initial systematic search retrieved 139 publications using different combinations of key terms. Based on our inclusion and exclusion criteria, eleven eligible publications were ultimately enrolled for the data pool in this meta-analysis [ 8 , 9 , 11 , 13 – 19 , 22 ] (Figure 1 ), altogether 5316 cancer patients. The general characteristics of enrolled studies are summarized in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Many of SNPs in XPG gene have been reported to be associated with the outcomes of various cancers [ 5 , 8 – 29 ]. The association between XPG rs2296147T>C polymorphism and clinical outcomes of cancer patients has been widely studied [ 8 , 9 , 11 , 13 – 19 , 22 ]. Bai et al observed that OC patients with XPG rs2296147T>C TT genotype were associated with better response to chemotherapy and longer OS than CC genotype (OR (95% CI) for ORR: 4.17 (1.64-11.54); HR (95% CI) for OS: 0.47 (0.17-0.94)) [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

“…Yi et al indicated that NSCLC patients carrying XPG rs2296147T>C TT+CT genotype had a significantly longer median PFS and OS than CC genotype (HR (95% CI) for PFS: 0.73(0.51-0.97); HR (95% CI) for OS: 0.66(0.48-0.99)). The XPG rs2296147 T>C TT+CT genotype contribute to the better survival of NSCLC [ 19 ]. Hu et al reported that individuals carrying XPG rs2296147T>C T allele was associated with better PFS and OS of NSCLC (HR (95% CI) for PFS: 0.52 (0.38-0.70); HR (95% CI) for OS: 0.49(0.36-0.68)) [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

“…XPG gene is located on chromosome 13q32-q33, and encodes a protein of 1186 amino acids, which containing 15 exons and 14 introns. Previous studies indicate that the XPG rs2296147T>C polymorphism is suspected to have relationship with the clinical outcomes of cancer patients, such as colorectal cancer (CRC) [ 8 – 11 ], epithelial ovarian cancer (EOC) [ 12 , 13 ], head and neck cancer(HNC) [ 14 ], non-small cell lung cancer (NSCLC) [ 15 – 19 ], gastric cancer (GC) [ 20 ] and osteosarcoma (OC) [ 21 , 22 ]. Published data from these studies have shown inconsistent results.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Predictive value ofXPGrs2296147T>C polymorphism on clinical outcomes of cancer patients

et al. 2016

View full text Add to dashboard Cite

The Xeroderma pigmentosum complementation group G (XPG) rs2296147T>C polymorphism is suspected to associate with the clinical outcomes of cancer patients. However, the results are inconsistent. This meta-analysis aimed to evaluate the reliable predictive value of XPG rs2296147T>C polymorphism on clinical outcomes of cancer patients. A total of 11 eligible studies were enrolled in this meta-analysis. Our results indicated that the cancer patients with TT and CT genotypes were significantly associated with better respond rates when compared with the CC genotype (TT versus (vs.) CC: odds ratio (OR) = 2.05, 95% confidence intervals (CIs), 1.32-3.20, P = 0.002; TT+CT vs. CC: OR= 1.57, 95% CI, 1.14-2.17, P = 0.005). The TT genotype and/or T allele might be associated with higher survival time for cancer patients than the CC genotype and/or C allele. The cumulative meta-analyses showed an apparent beneficial objective response of TT genotype on cancer patients. In conclusion, this meta-analysis suggests that the XPG rs2296147T>C polymorphism is associated with the clinical outcomes of cancer patients. The XPG rs2296147T>C polymorphism might be a predictive factor of prognosis in cancers patients and contribute to individual treatment in the future.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Predictive value ofXPGrs2296147T>C polymorphism on clinical outcomes of cancer patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…rs2296147 was the most significant SNP which associated with response rate. It was reported that rs2296147 was not only associated with cancer risk, but also related to prognosis of cancer 37 . There were also many studies showed that rs2296147 was associated with prognosis of advanced non-small cell lung cancer treated with platinum-based chemotherapy, and could predict the clinical outcomes of platinum-based chemotherapy 38 – 41 .…”

Section: Discussionmentioning

confidence: 99%

Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer

Song

Wang

Hong

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Nucleotide excision repair (NER) pathway plays critical roles in repairing DNA disorders caused by platinum. To comprehensively understand the association between variants of NER and clinical outcomes of platinum-based chemotherapy, 173 SNPs in 27 genes were selected to evaluate association with toxicities and efficiency in 1004 patients with advanced non-small cell lung cancer. The results showed that consecutive significant signals were observed in XPA, RPA1, POLD1, POLD3. Further subgroup analysis showed that GTF2H4 presented consecutive significant signals in clinical benefit among adenocarcimoma. In squamous cell carcinoma, rs4150558, rs2290280, rs8067195 were significantly associated with anemia, rs3786136 was significantly related to thrombocytopenia, ERCC5 presented consecutive significant signals in response rate. In patients receiving TP regimen, significant association presented in neutropenia, thrombocytopenia and gastrointestinal toxicity. Association with anemia and neutropenia were found in GP regimen. rs4150558 showed significant association with anemia in NP regimen. In patients > 58, ERCC5 showed consecutive significant signals in gastrointestinal toxicity. Survival analysis showed SNPs in POLD2, XPA, ERCC6 and POLE were significantly associated with progression free survival, SNPs in GTF2H4, ERCC6, GTF2HA, MAT1, POLD1 were significantly associated with overall survival. This study suggests SNPs in NER pathway could be potential predictors for clinical outcomes of platinum-based chemotherapy among NSCLC.

show abstract

An insight into clinical outcome of XPG polymorphisms in breast cancer

et al. 2018

View full text Add to dashboard Cite

XPG is a novel biomarker of clinical outcome in advanced non-small-cell lung cancer

Cited by 11 publications

References 17 publications

Predictive value ofXPGrs2296147T>C polymorphism on clinical outcomes of cancer patients

Predictive value ofXPGrs2296147T>C polymorphism on clinical outcomes of cancer patients

Single nucleotide polymorphisms of nucleotide excision repair pathway are significantly associated with outcomes of platinum-based chemotherapy in lung cancer

An insight into clinical outcome of XPG polymorphisms in breast cancer

Contact Info

Product

Resources

About